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INTRODUCTION
Preeclampsia (PE) is a multisystem pathological 
condition that occurs in the second half of pregnancy 
(after the 20th week), characterized by arterial 
hypertension in combination with proteinuria (≥3 g/l 
in daily urine), often edema and manifestations of 
polyorganic/polysystemic dysfunction/deficiency.[1]
According to the world literature and the World 
Health Organization, the incidence of PE is 2–8%.[1,3] 
PE remains an important cause of maternal, perinatal, 
and neonatal morbidity and mortality.[2,4]
Severe PE and eclampsia cause the risk of complications 
such as hemorrhages and cerebral edema, placental 
abruption, disseminated intravascular coagulation 
syndrome, massive obstetric hemorrhages, hemolysis, 
elevated liver enzyme levels, and low platelet count 
syndrome, hemorrhage and rupture of the liver capsule, 
pulmonary edema, adult respiratory distress syndrome, 
and acute renal and hepatic insufficiency.[1,15] In the 
following years of life, chronic hypertension, coronary 
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heart disease, and stroke become more common to 
such women (Bilano VL et al., 2014).[6]
Children born after preeclamptic pregnancies have a 
low weight and an increased risk of developing stroke, 
coronary heart disease, and metabolic syndrome in 
adulthood (Bilano VL et al., 2014).[1,6]
In the etiopathogenesis of PE, an important role 
is played by vascular reactions, which are based 
on generalized vasospasm causing ischemic and 
hypoxic changes in tissues with impaired function, the 
development of endothelial dysfunction, and multiple 
organ failure.[7,8]
MATERIALS AND METHODS
The study group included 459 women: 250 pregnant 
women with PE and 209 women with normal 
pregnancy (control group). The studied samples 
included individuals of Russian nationality who are 
natives of the Central Black Earth Region of Russia 
and have no relationship with each other. Clinical 
and laboratory examination of pregnant women was 
carried out on the basis of the Perinatal Center of the 
Belgorod Regional Clinical Hospital.
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All clinical studies were carried out based on the 
informed consent of the patients to the use of materials 
of therapeutic and diagnostic activities carried 
out during and after the period of hospitalization 
associated with PE for research purposes and were 
recorded according to the standards of the Ethics 
Committee of the Russian Federation.
PE was defined as the presence of hypertension, 
accompanied by proteinuria, as defined by a 24 h 
urine protein excretion more 300 mg.[1] The following 
qualitative and quantitative pathogenetically significant 
signs for PE were studied: Assessment of weight gain 
in pregnant women, edema and protein in the urine, 
and body mass index was calculated, coagulogram 
(fibrinogen, prothrombin ratio [PR], and partial 
thromboplastin time [PTT]) was studied, and thrombin 
time [TT]), blood chemistry (total protein, glucose, 
urea, creatinine, and bilirubin), systolic blood pressure 
(SBP), and diastolic blood pressure (DBP) levels before 
pregnancy and during pregnancy were measured.
During the study of the clinical and laboratory 
parameters of pregnant women, the nature of the 
distribution of these signs was assessed using the 
Shapiro–Wilk criterion.[9] Further, statistical analysis 
of the considered signs was carried out taking into 
account the nature of their distribution.[9]
It was found that the distribution of all the studied 
quantitative characters was not consistent with a 
normal distribution and, therefore, the median (Me) 
and interquartile range (Q25–Q75) were used to 
describe them, and Mann–Whitney test was used for 
comparative analysis.[9] Statistical data processing was 
carried out using Statistica 6.0 software package.[9]
RESULTS
The gestational age was 37–40 weeks. The average age 
of the main group was 27.11 ± 6.42 years (ranged from 18 
to 44 years) and of the control group - 26.5 ± 6.36 years 
(ranged from 18 to 42 years) (P > 0.05).
It was found that the systolic, diastolic, pulse, and 
mean blood pressure (MAP) in women with and 
without PE both statistically significantly differ from 
each other before and at the end of pregnancy [Table 1] 
(P < 0.01): Blood pressure is higher in those with PE 
than in women without PE. Along with this, significant 
differences were found in the examined groups 
according to clinical and laboratory parameters: The 
content of fibrinogen in the blood and the TT indicator 
in pregnant women with PE are higher, and the PTT, 
PR, and total protein content in the blood are lower 
compared with women without PE (P < 0.01). The 
blood glucose level in the studied groups of pregnant 
women was not statistically different (P = 0.06).
DISCUSSION
The results of this study demonstrate the differences in 
clinical and laboratory parameters in pregnant women 
with PE compared with women with physiological 
pregnancy.
First, pregnant women with PE are characterized 
by high blood pressure. According to other studies, 
increased SBP, DBP, and MAP during the first 
trimester significantly increase the risk of PE compared 
with women with normal blood pressure during 
pregnancy.[10,11] High blood pressure is also associated 
with shorter gestation and lower birth weights [12,13] In 
addition, women with PE have significantly higher 
risk of development of cardiovascular diseases, 
including hypertension and stroke.[14]
Second, the results of this study indicate a positive 
hemostatic potential in pregnant women with PE, 
which increases the risk of blood clots and is consistent 
with other literature data.[5] In turn, hypercoagulation 
leads to a decrease in placental perfusion of blood 
Table 1: The parameters of the distribution of clinical and clinical laboratory indicators in the study group of women
Parameters Pregnant women without PE Pregnant women with PE P
SBP before pregnancy, mmHg 105.00 (100.00–110.00) 110.00 (110.00–120.00) 0.000000
DBP before pregnancy, mmHg 70.00 (60.00–70.00) 70.00 (70.00–80.00) 0.000001
PBP before pregnancy, mmHg 40.00 (30.00–40.00) 40.00 (40.00–40.00) 0.000000
MAP before pregnancy, mmHg 81.67 (75.00–83.33) 83.33 (83.33–90.00) 0.0001
SBP at the end of pregnancy, mmHg 110.00 (100.00–115.00) 140.00 (130.00–150.00) 0.000000
DBP at the end of pregnancy, mmHg 70.00 (70.00–80.00) 90.00 (80.00–95.00) 0.000000
PBP at the end of pregnancy, mmHg 40.00 (30.00–40.00) 50.00 (45.00–60.00) 0.000000
MAP at the end of pregnancy, mmHg 85.00 (83.33–90.00) 106.67 (100.00–113.33) 0.000000
Fibrinogen levels, g/l 3.30 (2.90–3.80) 4.65 (4.10–5.10) 0.000000
PR, % 100.00 (100.00–100.00) 100.00 (90.00–100.00) 0.002
PTT, s 38.00 (34.50–41.00) 33.00 (28.00–36.00) 0.000000
TT, s 15.00 (12.00–16.00) 15.00 (13.00–17.00) 0.01
Total protein, g/l 69.75 (67.00–72.00) 63.00 (60.00–67.60) 0.000000
Blood glucose level, mmol/l 4.20 (3.80–4.70) 4.20 (3.80–4.80) 0.06
Me; Q25-Q75, interquartile range – the 25th and 75th percentiles; W: Shapiro–Wilk criterion; P: Significance level; SBP: Systolic blood pressure; DBP: Diastolic 
blood pressure; PBP: Pulse blood pressure; MAP: Mean arterial pressure; TT: Thrombin time, PTT: Partial thromboplastin time, PR: Prothrombin ratio; 
PE: Preeclampsia
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caused by microthrombi in placental blood vessels, 
which ultimately leads to placental ischemia 
underlying PE.[16]
Thus, as a result of this study, significant associations 
of blood pressure and hemostasis in pregnant women 
with PE were established, compared with women with 
physiological pregnancy.
The obtained results broaden the existing ideas about 
the role of maternal factors in the development of PE 
and make it possible to practice them in obstetrics.
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